BR102018073582A2
|
|
ENANTIOMER, PROCESS OF PREPARATION OF AN ENANTIOMER, USE OF THE ENANTIOMER, PHARMACEUTICAL COMPOSITION AND COMBINATION
|
EP3598975A1
|
|
Novel combinations of a h3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof
|
EP3378858A1
|
|
Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same
|
AU2013326470A1
|
|
A combination of adrenalin with an antidepressant for use in the treatment of shocks
|
EP2671883A1
|
|
New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
|
EP2671870A1
|
|
Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
|
EP2511275A1
|
|
Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
|
EP2462922A1
|
|
New form of administration of enkephalinase inhibitor
|
EP2447263A1
|
|
Benzazole derivatives as histamine H4 receptor ligands
|
EP2263672A1
|
|
Novel pharmaceutically acceptable salts of 4-(1H-imidazol-4-ylmethyl)pyridine and their therapeutical uses
|
CA2659754A1
|
|
Combination of modafinil and an antagonist or inverse agonist of the h3 receptor
|
EP2014653A1
|
|
Novel dicarboxylic acid derivatives as S1P1 receptor agonists
|
CN101442990A
|
|
New form of administration of racecadotril
|
TW200736238A
|
|
Process for preparing 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
|
EP1870405A1
|
|
Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
|
FR2902009A1
|
|
Use of a vasopeptidase inhibitor for the treatment of pulmonary arterial hypertension
|
US2008214542A1
|
|
Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands
|
EP1659112A1
|
|
Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor
|
EP1717235A2
|
|
Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
|
EP1717233A1
|
|
Histamine H3-receptor ligands and their therapeutic application
|